Avalo Therapeutics
AVTX

股本结构

单位：万股
公告日期 2025-11-06 2025-11-06 2025-08-07 2025-08-07 2025-05-12 2025-03-20
证券总股本 1813.40 1782.76 1315.24 1083.74 1082.76 1067.19
普通股本 1813.40 1782.76 1315.24 1083.74 1082.76 1067.19
优先股 未披露 1.94 未披露 2.47 2.47 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2025-11-03 2025-09-30 2025-08-06 2025-06-30 2025-03-31 2025-03-17
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2025-11-06 1813.40 未披露 定期报告 2025-11-03
2025-11-06 1782.76 1.94
更多>>
From June 30, 2025 to September 30, 2025 Issuance of common stock in exchange for retirement of Series C Preferred Stock Issuance of common stock pursuant to ATM Program, net
2025-09-30
2025-08-07 1315.24 未披露 定期报告 2025-08-06
2025-08-07 1083.74 2.47
更多>>
From March 31, 2025 to June 30, 2025 Shares purchased through employee stock purchase plan
2025-06-30
2025-05-12 1082.76 2.47
更多>>
From December 31, 2024 to March 31, 2025 Issuance of common stock in exchange for retirement of Series C Preferred Stock Vesting of Restricted Stock Units net of shares withheld for taxes
2025-03-31
2025-03-20 1067.19 未披露 定期报告 2025-03-17
2025-03-20 1047.19 2.49
更多>>
From December 31, 2023 to December 31, 2024 Impact of reverse split fractional share round-up Issuance of common stock pursuant to AlmataBio Transaction Issuance of common stock in exchange for retirement of Series C Preferred Stock Issuance of common shares pursuant to warrant exercises Shares purchased through employee stock purchase plan
2024-12-31
2024-11-12 1046.36 2.49 定期报告 2024-11-08
2024-11-07 1039.40 未披露 定期报告 2024-11-06
2024-11-07 968.24 1.37
更多>>
From June 30,2024 to September 30,2024 Retirement of Series C Preferred Stock in exchange for issuance of common stock Issuance of common stock in exchange for retirement of Series C Preferred Stock
2024-09-30
2024-08-05 103.41 2.24 定期报告 2024-07-05
2024-05-13 103.41 2.24
更多>>
From December 31, 2023 to March 31, 2024 Impact of reverse split fractional share round-up Issuance of common stock pursuant to Almata Transaction
2024-03-31
2024-03-29 103.41 未披露 定期报告 2024-03-27
2024-03-29 86.25 未披露 定期报告 2024-03-15
2024-03-29 80.17 未披露
更多>>
From December 31, 2022 to December 31, 2023 Shares purchased through employee stock purchase plan Retirement of common shares in exchange for pre-funded warrants Issuance of common stock and warrants in underwritten public offering, net Impact of reverse stock split fractional share round-up Issuance of common shares pursuant to ATM Program, net Exercise of pre-funded warrants for common shares
2023-12-31
2023-12-28 80.16 未披露
更多>>
Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.
2023-12-29
2023-11-09 19238.24 未披露
更多>>
From June 30, 2023 to September 30, 2023 Issuance of common shares pursuant to ATM Program, net Exercise of pre-funded warrants for common shares
2023-09-30
2023-08-07 2094.54 未披露 定期报告 2023-08-04
2023-08-03 2024.94 未披露 定期报告 2023-08-02
2023-08-03 1403.69 未披露
更多>>
From March 31,2023 to June 30,2023 Issuance of common shares pursuant to ATM Program, net Retirement of common shares in exchange for pre-funded warrants Exercise of pre-funded warrants for common shares Shares purchased through employee stock purchase plan
2023-06-30
2023-03-29 1320.05 未披露 定期报告 2023-03-24
2023-02-03 1318.41 未披露
更多>>
Common Stock offered 3,770,000 shares by the company
2023-02-07
2023-03-29 943.05 未披露
更多>>
From December 31, 2021 to December 31, 2022 Issuance of common shares pursuant to ATM Program, net Restricted stock units vested during period Shares purchased through employee stock purchase plan Impact of reverse stock split fractional share round-up
2022-12-31
2022-11-07 941.41 未披露
更多>>
From June 30, 2022 to September 30, 2022 Impact of reverse stock split fractional share round-up
2022-09-30
2022-08-04 941.41 未披露 定期报告 2022-08-02
2022-07-07 940.57 未披露
更多>>
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022.
2022-07-08
2022-07-07 11286.87 未披露 定期报告 2022-07-07
2022-03-02 11279.42 未披露
更多>>
From December 31, 2020 to December 31, 2021 Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net Issuance of common stock in underwritten public offering, net Issuance of common shares pursuant to ATM Program, net Conversion of preferred stock to common stock Exercise of stock options Exercise of pre-funded warrants Shares purchased through employee stock purchase plan Restricted stock units vested during period
2021-12-31
2021-11-09 11231.78 未披露
更多>>
From June 30, 2021 to September 30, 2021 Issuance of common stock in underwritten public offering, net Issuance of common stock pursuant to ATM Program, net
2021-09-30
2021-09-17 10850.90 未披露
更多>>
1.Common Stock offered by company 12,500,000 shares. 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 96,008,951 shares outstanding as of June 30, 2021.
2021-09-17
2021-08-02 9600.90 未披露
更多>>
From March 31, 2021 to June 30, 2021 Conversion of preferred stock to common stock Restricted stock units vested during period Shares purchased through employee stock purchase plan Exercise of stock options
2021-06-30
2021-05-13 9547.18 未披露 定期报告 2021-05-11
2021-04-27 9545.72 未披露 定期报告 2021-04-22
2021-05-13 8910.48 125.71
更多>>
From December 31, 2020 to March 5, 2021 Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net Exercise of stock options and warrants
2021-03-05
2021-03-08 8910.48 未披露 定期报告 2021-03-04
2021-01-12 8722.31 未披露
更多>>
1.Common Stock offered by the company 12,323,077 shares. 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 74,900,047 shares outstanding as of September 30, 2020.
2021-01-12
2021-03-08 7500.41 125.71
更多>>
From December 31, 2019 to December 31, 2020 Conversion of preferred stock to common stock Issuance of shares related to Aevi Merger Issuance of shares pursuant to registered direct offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Issuance of shares of common stock in underwritten public offering, net of offering costs Exercise of stock options and warrants Restricted stock units vested during period Restricted stock units withheld for taxes Shares purchased through employee stock purchase plan
2020-12-31
2020-11-09 7491.00 未披露 定期报告 2020-11-05
2020-08-06 7490.00 125.71
更多>>
From March 31, 2020 to June 30, 2020 Issuance of shares of common stock in underwritten public offering, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
2020-06-30
2020-06-11 7276.03 未披露
更多>>
1.Common Stock offered by us13,200,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 59,560,252 shares outstanding as of March 31, 2020
2020-06-11
2020-04-28 5960.60 未披露 定期报告 2020-04-23
2020-05-07 5956.03 125.71
更多>>
From December 31, 2019 to March 31, 2020 Conversion of preferred stock to common stock Issuance of shares related to Aevi Merger Issuance of shares pursuant to registered direct offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants
2020-03-31
2020-03-11 5760.90 未披露 定期报告 2020-03-09
2020-02-05 5371.57 未披露 定期报告 2020-02-05
2020-02-04 5240.94 未披露 定期报告 2020-01-30
2020-03-11 4438.42 285.71
更多>>
from December 31, 2018 to December 31, 2019 Issuance of shares of common stock in underwritten public offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during the period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
2019-12-31
2019-12-30 4415.65 未披露 定期报告 2019-12-10
2019-11-14 4410.68 285.71
更多>>
From June 30, 2019 to September 30, 2019 Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes
2019-09-30
2019-09-27 4410.67 未披露 定期报告 2019-09-16
2019-08-08 4290.67 未披露 定期报告 2019-08-05
2019-08-08 4289.83 285.71
更多>>
from March 31, 2019 to June 30, 2019 Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
2019-06-30
2019-06-19 4278.62 未披露 定期报告 2019-06-10
2019-05-09 4275.37 未披露
更多>>
from December 31, 2018 to March 31, 2019 Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period
2019-03-31
2019-03-18 4265.37 未披露 定期报告 2019-03-11
2019-03-18 4080.42 未披露
更多>>
from December 31, 2017 to December 31, 2018 Issuance of contingently issuable shares in acquisition of TRx Issuance of shares pursuant to common stock private placement, net of offering costs Issuance of shares in acquisition of Ichorion assets Exercise of stock options and warrants Shares purchased through employee stock purchase plan
2018-12-31
2018-12-27 4080.42 未披露 定期报告 2018-12-20
2018-11-13 4080.61 未披露 定期报告 2018-11-06
2018-11-13 4067.96 未披露 定期报告 2018-09-30
2018-10-02 4067.96 未披露 定期报告 2018-09-26
2018-09-07 3488.04 未披露 定期报告 2018-09-04
2018-08-20 3384.64 未披露 定期报告 2018-08-14
2018-08-09 3384.45 未披露 定期报告 2018-08-06
2018-08-09 3379.07 未披露 定期报告 2018-06-30
2018-05-11 3141.30 未披露 定期报告 2018-05-09
2018-05-11 3141.03 未披露 定期报告 2018-03-31
2018-04-02 3137.98 未披露 定期报告 2018-03-16
2018-04-02 3126.70 未披露
更多>>
from December 31, 2016 to December 31, 2017 Issuance of common stock from sale of shares under common stock purchase agreement, net of offering costs Issuance of preferred and common stock to Armistice Capital, net of offering costs Conversion of Armistice Capital preferred to common stock Issuance of shares in acquisition of TRx Shares purchased through employee stock purchase plan
2017-12-31
2017-11-07 2605.49 未披露 定期报告 2017-09-30
2017-08-14 2605.49 未披露
更多>>
The Company received shareholder approval for this transaction on June 30, 2017, at which time the warrants became exercisable and the Series A Preferred Stock became convertible into common stock. Armistice converted all of the Series A Preferred Stock into 11,940,000 shares of common stock on July 6, 2017.
2017-08-14
2017-08-14 1411.49 0.42 定期报告 2017-06-30
2017-05-09 1408.15 未披露 定期报告 2017-05-09
2017-05-09 1090.12 未披露 定期报告 2017-03-31
2017-03-31 1079.96 未披露 定期报告 2017-03-24
2017-03-14 1074.50 未披露 定期报告 2017-03-10
2017-03-14 943.41 未披露
更多>>
from December 31, 2015 to December 31, 2016 Issuance of common stock from sale of shares under common stock purchase agreement, net of offering costs Shares purchased through employee stock purchase plan
2016-12-31
2016-11-08 926.41 未披露 定期报告 2016-11-01
2016-11-08 907.51 未披露 定期报告 2016-09-30
2016-03-23 865.01 未披露
更多>>
from December 31, 2014 to December 31, 2015 Issuance of securities in initial public offering, including over-allotment and underwriters' unit purchase option, net of offering costs and underwriting discounts, commissions and expenses Issuance of common stock for conversion of preferred stock upon closing of initial public offering On September 1, 2015, the Company filed an amendment to its amended and restated certificate of incorporation effecting a 1-for-28 reverse stock split of its common stock.
2015-12-31
2015-11-13 863.01 未披露
更多>>
In October 2015 the Company completed its IPO. In connection with the closing of the IPO, all outstanding shares of the Company’s Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock were converted into 3,980,422 shares of Common Stock. A 1 for 28 reverse stock split of our common stock effected on September 1, 2015;
2015-11-13
2015-09-22 64.97 9913.96 定期报告 2015-06-30
From June 30, 2025 to September 30, 2025 Issuance of common stock in exchange for retirement of Series C Preferred Stock Issuance of common stock pursuant to ATM Program, net
From March 31, 2025 to June 30, 2025 Shares purchased through employee stock purchase plan
From December 31, 2024 to March 31, 2025 Issuance of common stock in exchange for retirement of Series C Preferred Stock Vesting of Restricted Stock Units net of shares withheld for taxes
From December 31, 2023 to December 31, 2024 Impact of reverse split fractional share round-up Issuance of common stock pursuant to AlmataBio Transaction Issuance of common stock in exchange for retirement of Series C Preferred Stock Issuance of common shares pursuant to warrant exercises Shares purchased through employee stock purchase plan
From June 30,2024 to September 30,2024 Retirement of Series C Preferred Stock in exchange for issuance of common stock Issuance of common stock in exchange for retirement of Series C Preferred Stock
From December 31, 2023 to March 31, 2024 Impact of reverse split fractional share round-up Issuance of common stock pursuant to Almata Transaction
From December 31, 2022 to December 31, 2023 Shares purchased through employee stock purchase plan Retirement of common shares in exchange for pre-funded warrants Issuance of common stock and warrants in underwritten public offering, net Impact of reverse stock split fractional share round-up Issuance of common shares pursuant to ATM Program, net Exercise of pre-funded warrants for common shares
Avalo Therapeutics, Inc. announced a 1-for-240 reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time on December 28, 2023.
From June 30, 2023 to September 30, 2023 Issuance of common shares pursuant to ATM Program, net Exercise of pre-funded warrants for common shares
From March 31,2023 to June 30,2023 Issuance of common shares pursuant to ATM Program, net Retirement of common shares in exchange for pre-funded warrants Exercise of pre-funded warrants for common shares Shares purchased through employee stock purchase plan
Common Stock offered 3,770,000 shares by the company
From December 31, 2021 to December 31, 2022 Issuance of common shares pursuant to ATM Program, net Restricted stock units vested during period Shares purchased through employee stock purchase plan Impact of reverse stock split fractional share round-up
From June 30, 2022 to September 30, 2022 Impact of reverse stock split fractional share round-up
Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced a one-for-twelve reverse stock split of the Company’s common stock, par value $0.001, which will be effective at 5:00 pm Eastern Time tomorrow, July 7, 2022.
From December 31, 2020 to December 31, 2021 Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net Issuance of common stock in underwritten public offering, net Issuance of common shares pursuant to ATM Program, net Conversion of preferred stock to common stock Exercise of stock options Exercise of pre-funded warrants Shares purchased through employee stock purchase plan Restricted stock units vested during period
From June 30, 2021 to September 30, 2021 Issuance of common stock in underwritten public offering, net Issuance of common stock pursuant to ATM Program, net
1.Common Stock offered by company 12,500,000 shares. 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 96,008,951 shares outstanding as of June 30, 2021.
From March 31, 2021 to June 30, 2021 Conversion of preferred stock to common stock Restricted stock units vested during period Shares purchased through employee stock purchase plan Exercise of stock options
From December 31, 2020 to March 5, 2021 Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net Exercise of stock options and warrants
1.Common Stock offered by the company 12,323,077 shares. 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 74,900,047 shares outstanding as of September 30, 2020.
From December 31, 2019 to December 31, 2020 Conversion of preferred stock to common stock Issuance of shares related to Aevi Merger Issuance of shares pursuant to registered direct offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Issuance of shares of common stock in underwritten public offering, net of offering costs Exercise of stock options and warrants Restricted stock units vested during period Restricted stock units withheld for taxes Shares purchased through employee stock purchase plan
From March 31, 2020 to June 30, 2020 Issuance of shares of common stock in underwritten public offering, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
1.Common Stock offered by us13,200,000 shares 2.The number of shares of common stock to be outstanding after this offering is based on an aggregate of 59,560,252 shares outstanding as of March 31, 2020
From December 31, 2019 to March 31, 2020 Conversion of preferred stock to common stock Issuance of shares related to Aevi Merger Issuance of shares pursuant to registered direct offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants
from December 31, 2018 to December 31, 2019 Issuance of shares of common stock in underwritten public offering, net of offering costs Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during the period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
From June 30, 2019 to September 30, 2019 Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes
from March 31, 2019 to June 30, 2019 Exercise of stock options and warrants Restricted Stock Units vested during period Restricted Stock Units withheld for taxes Shares purchased through employee stock purchase plan
from December 31, 2018 to March 31, 2019 Issuance of shares pursuant to common stock private placement, net of offering costs Exercise of stock options and warrants Restricted Stock Units vested during period
from December 31, 2017 to December 31, 2018 Issuance of contingently issuable shares in acquisition of TRx Issuance of shares pursuant to common stock private placement, net of offering costs Issuance of shares in acquisition of Ichorion assets Exercise of stock options and warrants Shares purchased through employee stock purchase plan
from December 31, 2016 to December 31, 2017 Issuance of common stock from sale of shares under common stock purchase agreement, net of offering costs Issuance of preferred and common stock to Armistice Capital, net of offering costs Conversion of Armistice Capital preferred to common stock Issuance of shares in acquisition of TRx Shares purchased through employee stock purchase plan
The Company received shareholder approval for this transaction on June 30, 2017, at which time the warrants became exercisable and the Series A Preferred Stock became convertible into common stock. Armistice converted all of the Series A Preferred Stock into 11,940,000 shares of common stock on July 6, 2017.
from December 31, 2015 to December 31, 2016 Issuance of common stock from sale of shares under common stock purchase agreement, net of offering costs Shares purchased through employee stock purchase plan
from December 31, 2014 to December 31, 2015 Issuance of securities in initial public offering, including over-allotment and underwriters' unit purchase option, net of offering costs and underwriting discounts, commissions and expenses Issuance of common stock for conversion of preferred stock upon closing of initial public offering On September 1, 2015, the Company filed an amendment to its amended and restated certificate of incorporation effecting a 1-for-28 reverse stock split of its common stock.
In October 2015 the Company completed its IPO. In connection with the closing of the IPO, all outstanding shares of the Company’s Series A Convertible Preferred Stock, Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock were converted into 3,980,422 shares of Common Stock. A 1 for 28 reverse stock split of our common stock effected on September 1, 2015;
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。